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Abstract
Leber’s hereditary optic neuropathy (LHON) is a maternally inherited blinding disease characterized by degeneration of retinal
ganglion cells (RGCs) and consequent optic nerve atrophy. Peculiar features of LHON are incomplete penetrance and gender
bias, with a marked male prevalence. Based on the different hormonal metabolism between genders, we proposed that
estrogens play a protective role in females and showed that these hormones ameliorate mitochondrial dysfunction in LHON
through the estrogen receptors (ERs). We also showed that ERβ localize to the mitochondria of RGCs. Thus, targeting ERβmay
become a therapeutic strategy for LHON specifically aimed at avoiding or delaying the onset of disease in mutation carriers.
Here, we tested the effects of ERβ targeting on LHONmitochondrial defectivemetabolism by treating LHON cybrid cells carrying
the m.11778G>A mutation with a combination of natural estrogen-like compounds that bind ERβ with high selectivity. We
demonstrated that these molecules improve cell viability by reducing apoptosis, inducing mitochondrial biogenesis and
strongly reducing the levels of reactive oxygen species in LHON cells. These effects were abolished in cells with ERβ knockdown
by silencing receptor expression or by using specific receptor antagonists. Our observations support the hypothesis that
estrogen-like molecules may be useful in LHON prophylactic therapy. This is particularly important for lifelong disease
prevention in unaffected LHON mutation carriers. Current strategies attempting to combat degeneration of RGCs during the
acute phase of LHON have not been very effective. Implementing a different and preemptive approach with a low risk profile
may be very helpful.
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Introduction
Leber’s Hereditary Optic Neuropathy (LHON [MIM 535000]) is a
maternally inherited disease characterized by a subacute select-
ive degeneration of retinal ganglion cells (RCGs) leading to optic
nerve atrophy and loss of central vision, mostly in young men.
LHON is almost always owing to one of three frequent pathogenic
point mutations of mitochondrial DNA (mtDNA), affecting
the complex I subunits genes MT-ND4 (m.11778G>A), MT-ND1
(m.3460G>A) and MT-ND6 (m.14484T>C) (1). With an estimated
frequency of ∼1 in 50 000 in Europe (2,3,4,5), LHON represents
one of the most common mitochondrial disorders and its treat-
ment is an unmet clinical need. In fact, although the administra-
tion of antioxidants such as idebenone and EPI-743 showed
encouraging results in promoting partial recovery of visual func-
tion (6,7,8,9), optic atrophy and permanent blindness still remain
the usual outcomes of LHON. Peculiar features of LHON are
incomplete penetrance and significant gender bias. LHON patho-
genic mutations are usually homoplasmic (all mitochondrial
DNA molecules are mutated), yet only ∼50% of male and 10% of
female mutation carriers lose vision (10,11). Investigations have
revealed at least four modulators of LHON penetrance: the ana-
tomical variation of the optic nerve head size leading to the
’crowded disc’ as a risk factor (12), mtDNA background haplo-
types increasing penetrance (13,14), ill-defined nuclear DNA
background modifiers (15,16,17) and environmental factors
such as tobacco smoking acting as disease triggers (18,19).
More recently, stemming from the male prevalence, we pro-
posed that estrogens play a protective role in females by mitigat-
ing the deleterious effect of LHON mutations on mitochondrial
functions (20). By using transmitochondrial cybrids (herein cy-
brids), we demonstrated that 17β-estradiol (E2) reduces reactive
oxygen species (ROS) production and ameliorates cell energetic
competence by inducing mitochondrial biogenesis. These find-
ings fit our ex vivo and in vitro studies showing that unaffected
mutation carriers (i.e. individuals carrying the mutation that
have not developed the disease after 35 years of age) display
the most efficient compensatory mitochondrial biogenesis, as
compared with controls and LHON affected individuals (21). Al-
together, our observations provide an explanatory framework
for incomplete penetrance with male prevalence in LHON and
point to the crucial role played by the genetic and hormonal
modulation of mitochondrial biogenesis.
Interestingly, the positive effects of estrogens aremediated by
estrogen receptors (ERs), and ERβ, but not the ERα subtype, loca-
lizes to mitochondria of RGCs (20). Thus, targeting ERβmay be an
effective therapeutic strategy for young unaffected carriers of the
LHON mutation, to specifically avoiding or delaying the onset of
disease. The option to target the ERβ pathway for therapeutic
purposes is more attractive and safer than nonspecific targeting
involving also ERα. This is because ERα, but not ERβ, activation
mediates the undesirable side effects such as gynecomastia
and decreased libido in men and elevated risk for breast and
endometrial cancers in women (22). Furthermore, signaling
through ERβ has been shown to play a major role in estrogen-
mediated neuroprotection, myelination and promotion of neural
synaptic plasticity (23,24,25). Accordingly, in the last few years, a
mounting number of studies have shown the efficacy of ERβ-se-
lective agonists in experimental models of neurodegenerative
disease and other disorders, including autoimmune diseases,
endometriosis, depression, hypertension and cancer (for a
review, see 26). Presently, natural and synthetic ERβ agonists
are being studied in human cancer, schizophrenia andmetabolic
syndrome (www.clinicaltrials.gov).
In the present work, we tested the effects of ERβ targeting on
LHONmitochondrial defective metabolism by treating LHON cy-
brids carrying the m.11778G>A mutation with a combination of
natural estrogen-like compounds (i.e. phytoestrogens genistein,
G; daidzein, D and equol, Eq). This formulation was previously
shown to bind ERβ with high selectivity, leading to a higher effi-
cacy/safety profile as compared with single or other combined
formulations (27). We here demonstrate that the phytoestrogens
formulation improved cell viability by reducing apoptosis, indu-
cing mitochondrial biogenesis and sharply reducing ROS levels
in LHON cybrids. Most of these effects were abolished by ERβ
knockdown.
Results
Phytoestrogens ameliorate LHON cell viability
in galactose medium by reducing apoptosis
LHON cybrids growth in galactosemediumdisplay reduced viabil-
ity as compared with controls because of apoptotic death (28,29).
As we previously demonstrated, supplementation of medium
with E2 rescued this pathological phenotype (20). We here show
that incubation of LHON cells with a combination of the phytoes-
trogens G, D and Eq (each at 100 n) increased viability (up to 70%
as compared with vehicle) after 48 h incubation in galactose me-
dium and decreased the rate of apoptosis (up to 50%) after 24 h.
These results were comparable with those obtained with 100-n
E2 (Fig. 1A and B). The phytoestrogen treatment did not affect via-
bility of control cells in galactosemedium (Supplementary Mater-
ial, Fig. S1A). Furthermore, supplementation with either E2 or
single phytoestrogens did not impact cell growth rate of mutant
or control cybrids in glucose medium (Supplementary Material,
Fig. S1B). Interestingly, the rescue in viability of LHON cells was
significantly milder when the phytoestrogens G, D or Eq were
added alone at 100 n (Supplementary Material, Fig. S1C). This
last observation is in agreement with previous results by Zhao
et al. (2009) showing that, when used in combination, the phytoes-
trogens G, D and Eq result in an overall improved efficacy as
comparedwith the isolated compounds used at the same concen-
tration (27). In addition, to verify that the better effect of the G+D
+Eq combination was not merely due to an overall increased con-
centration of the estrogen-likemolecules,we evaluated the effects
of 300 n of G, D and Eq alone on cells viability and showed no
significant effect as comparedwith vehicle in this setting (Supple-
mentary Material, Fig. S1D).
ERβ knockdown abolishes the effect of phytoestrogens
on cell viability
To verify whether the effect of the G+D+Eq formulation on LHON
cell viability was mediated by ERβ, we used two different
approaches. First, we performed a transient silencing of the two
ER isoforms by using specific siRNAs. As shown in Figure 1C, ERβ
silencing (ERβ-) completely abolished the rescue effect of the G+D
+Eq combination after 24 h incubation in galactose medium,
whereas ERα silencing (ERα-) did not. The efficiency of silencing
was evaluated by western blot analysis (Fig. 1D).
The second approach involved the use of selective pharmaco-
logic antagonists of the two ER isoforms. Again, pre-incubation of
LHON cybrids with 100 n of the selective ERβ antagonist PHTPP
abolished the effect of the G+D+Eq combination. In contrast, the
inhibition of ERα by the MPP dihydrochloride (MPP) antagonist
had no effect (Fig. 1E).
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The phytoestrogen formulation induces mitochondrial
biogenesis through ERβ activation
In previous work, we showed that LHON mutation carriers dis-
play a more efficient mitochondrial biogenesis as compared
with controls. This feature is more evident in unaffected carriers
as comparedwith affected individuals, pointing to compensatory
mitochondrial biogenesis as a modulator of disease penetrance
(21). We have also shown that the beneficial effect of estrogens
on LHON cell metabolism is largely mediated by the induction
of mitochondrial biogenesis (20). Thus, we analyzed markers of
mitochondrial biogenesis and mitochondrial density in LHON
and control cells treated with the phytoestrogens formulation.
As shown in Figure 2A, after 24 h incubation in glucose me-
dium supplemented with G+D+Eq (100 n each), we observed a
significant and coordinated induction (up to 2.5-fold increase)
of the regulators of mitochondrial biogenesis SIRT1, PGC1α and
NRF1. The key components of mitochondrial transcription and
replication machinery TFAM and POLG, and the nuclear- and
mitochondrial-encoded respiratory chain subunits MTND6,
NDUFA9,MTCOI and COIVwere also upregulated. Gene induction
was more evident in LHON as compared with controls and was
fully inhibitedwhen cellswere pre-incubatedwith the ERβ antag-
onist PHTPP. In contrast, when the ERα antagonist was added to
the medium the induction of mitochondrial biogenesis was still
evident, although to a lesser degree (Fig. 2A). We then evaluated
the expression level of proteins belonging to different mitochon-
drial compartments (matrix, inner and outer mitochondrial
membrane) showing a general upregulation in treated cells,
more evident in LHON (Fig. 2B and C).
The upregulation of mitochondrial proteins was associated
with an increase in mitochondrial density, as evaluated by ultra-
structure and morphometric analysis and expressed both as the
numberofmitochondria per 100 μm2andas amitochondrial/cyto-
plasmic area ratio (Fig. 3B). As shown in Figure 3A, treatment with
phytoestrogens did not impact on mitochondrial size and shape.
Induction of mitochondrial biogenesis leads to increased
respiratory competence of LHON cybrids
To assesswhether induction ofmitochondrial biogenesis reflects
into improvedmitochondrial energetics,weevaluated the respiration
Figure 1. Viability of LHON cybrids treated with 17β-estradiol or with a phytoestrogens formulation. (A) Viability of control (WT) and LHON cybrids (11778) evaluated after
48 h of incubation in galactosemedium supplementedwith either 100 n 17β-estradiol (E2), a combination of G+D+Eq (100 n each) or vehicle. The number of viable cells
in galactose is normalized to the number of viable cells in glucose at the same time point. Data are the mean ± SEM of four experiments in duplicate on twomutants and
two control cybrids clones. (B) Apoptotic cell death of WT and LHON cybrids after 24 h of incubation in galactose medium supplemented with either 100 n 17β-estradiol
(E2), a combination of G+D+Eq (100 n each) or vehicle. Data are expressed as a ratio between the percentage of apoptotic cells in galactose and in glucose medium. Data
are mean ± SEM of three experiments on two mutants and two control cybrid clones. ##P < 0.01; ####P < 0.0001 for 11778 vehicle versus WT vehicle (T-student). **P < 0.01;
***P < 0.001 for 11778 treated versus 11778 vehicle (ANOVA test). (C) Viability of LHON cybrids transiently transfected with either a specific siRNA against ERβ (ERβ-negative
clones, ERβ-) or ERα (ERα-negative clones, ERα-). An empty siRNA was used as a negative control (empty). Viability was evaluated after 24 h of incubation in galactose
medium±G+D+Eq (100 n each) or vehicle. The number of viable cells in galactose was normalized for the number of viable cells in glucose at the same time point.
Data are mean ± SEM of three experiments in duplicate on two cybrid clones. **P < 0.01, ***P < 0.001 for treated versus vehicle (T-student). (D) Representative western
blot on transiently transfected cybrids showing significant reduction of ERβ but not ERα protein in ERβ-negative clones and significant reduction of ERα but not ERβ
protein in ERα-negative clones. The β-actin protein was used as housekeeping. (E) Viability of LHON cybrids in the presence of either the selective ERβ antagonist
PHTPP (P) or the selective ERα antagonist MPP (M) added 30 min before G+D+Eq to the medium. The number of viable cells in galactose medium was normalized for
the number of viable cells in glucose medium after 48 h. Data are mean ± SEM of three experiments in duplicate on two clones. **P < 0.01 for 11778 treated versus
11778 vehicle (ANOVA test).
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capability of mutant and control cybrids by using both the Clark-
type electrode and the microscale oxygraphy. As expected, we
observed reduced oxygen consumption in LHON as compared
with controls. Treatment with the G+D+Eq formulation led to a
significant increase in both basal oxygen consumption rate (up
to 2-fold in LHON) and maximal respiration capacity after 24 h
(Fig. 3C and D).
To further characterize the energetic competence of cybrid
cells, we measured the ATP synthesis driven by CI (pyruvate/
malate) and CII (succinate) substrates in cells incubated for 24 h
in glucose medium with or without the G+D+Eq combination.
Again, as expected, wemeasured a reduced ATP synthesis driven
by CI substrates in LHON cybrids compared with controls. In
these conditions of maximal phosphorylation, we failed to
appreciate any differences between treated and untreated cells
(Supplementary Material, Fig. S2) supporting the hypothesis
that estrogenmainly acts by inducing an overall increase inmito-
chondrial biogenesis.
The phytoestrogen formulation decreases oxidative
stress in cybrid cells
There is previous evidence that production of mitochondrial ROS
is significantly increased in LHONcybrids (30,31) and supplemen-
tation with E2 significantly reduced superoxide (O2
−) levels (20).
Thus, we investigated mitochondrial O2
− levels in treated and
untreated cells using the MitoSOXTM Red fluorescence probe.
We showed that LHON cybrids presented higher O2
− levels as
compared with controls in basal condition (glucose medium).
Levels increased further when LHON cells were incubated 1 h in
galactose medium. Supplementation with phytoestrogens dra-
matically reduced O2
− levels both in glucose and galactose
(Fig. 4A). We confirmed, by flow cytometry, a significantly higher
(up to 1.3-fold) production of O2
− in LHON as compared with
controls. Again supplementation with the G+D+Eq formulation
substantially rescued this pathologic phenotype (Fig. 4A). The re-
duction of O2
−was paralleled, within 1 h, by the activation of the
mitochondrial isoform of superoxide dismutase (SOD), the Man-
ganese (Mn) SOD (Fig. 4B). Finally, we measured H2O2 levels by a
luminescent assay. In basal conditions, LHON cybrids showed
higher amounts of H2O2 levels (up to 2-fold increase) as compared
with controls, and again, phytoestrogen treatment led to a
1.2-fold decrease (Fig. 4C).
The beneficial effects of phytoestrogens also occurred
in cells from patients in the context of their nuclear
background
All the results presented were obtained in cybrids, a cell model
that evaluates the effect of mtDNA mutations in a neutral nu-
clear background (i.e. osteosarcoma cell line). Since we showed
that a different nuclear background between affected and
Figure 2. Evaluation ofmitochondrial biogenesis in control and LHON cybrids treatedwith the phytoestrogen formulation. (A) The relativemRNA expression of themaster
regulators of mitochondrial biogenesis (SIRT1, PGC1 and NRF1), the key components of the mitochondrial transcription and replication machinery (TFAM and POLG) and
the nuclear- andmitochondrial-encoded respiratory chain subunits (ND6,NDUFA9, COX I and COX IV) were evaluated by real-time PCR analysis on control (WT) and LHON
(11778) cells incubated 24 h in glucosemediumsupplementedwith G+D+Eq (100 n each) orwith vehicle (V). In a subset of experiments, LHON cybridswerepre-incubated
with 100 n of either the selective ERβ antagonist PHTPP (P) or the selective ERα antagonistMPP (M). Data are expressed as treated/vehicle ratio and aremean ± SEMof three
experiments in duplicate on two mutant and two cybrid clones. *P < 0.05, **P < 0.01, ***P < 0.001 for treated cells versus vehicle (T-student) (dark gray =WT; light
gray = LHON) (B and C). Protein expression evaluated on control and LHON cells incubated 24 h in glucose medium supplemented with G+D+Eq or vehicle (V):
representative western blot and densitometry are shown (mean ± SEM). Protein level was expressed as treated/vehicle ratio. Experiments were performed at least in
duplicate for all samples. *P < 0.05, **P < 0.01 for treated cells versus vehicle (T-student).
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unaffected LHON carriers modulates the penetrance of the
mtDNAmutation (21), we evaluated the effect of phytoestrogens
on fibroblasts derived from affected and unaffected mutation
carriers and controls.
We confirmed that in galactose medium fibroblasts from con-
trols andunaffected LHONcarriers grewat a similar rate,whereas
fibroblasts from affected individuals grew at a significantly
slower rate (21). This pathologic phenotype was completely res-
cued by supplementation of medium with the G+D+Eq formula-
tion. Phytoestrogens had no significant effect on the growth rate
of controls and unaffected carriers (Fig. 5B).
As expected, we found that ERβ localized to the nucleus and
co-localized with the mitochondrial network of fibroblasts
(Supplementary Material, Fig. S3).
Discussion
A formulation of phytoestrogens consisting of G+D+Eq led to the
rescue ofmitochondrial dysfunction in LHON cybrids, at a similar
magnitude as using E2. Multiple pathways with different timings
may possibly drive this rescue. The earliest effect of phytoestro-
gens is probably on oxidative stress, as exemplified byan increase
Figure 3. The phytoestrogens formulation increases mitochondrial density and ameliorates the bioenergetics competence of the cells. (A) Representative ultrastructural
images of control (WT) and LHON (11778) cybrids incubated 24 h in glucose medium supplemented with G+D+Eq (100 n each) or vehicle. Inserts represent higher
magnification images showing mitochondrial cristae. (B) For each condition, 15 random fields at 8000× magnification were acquired and the number of mitochondria
per 100 μm2 (upper panel) and mitochondrial/cytoplasmic area ratio (bottom panel) were obtained by using ImageJ 64 1.48v. Data are expressed as treated/vehicle
ratio and are mean ± SEM of two experiments on two control and two mutant cybrid clones. **P < 0.01, ***P < 0.001, ****P < 0.0001 for treated cells versus vehicle
(T-student). (C) Rate of oxygen consumption in control (WT) and LHON (11778) cells treated with G+D+Eq (100 n each) or vehicle for 24 h. Data are mean ± SEM of two
experiments on two control and two mutant cybrid clones. *P < 0.05 for treated cells versus vehicle (T-student). (D) OCR values were obtained in WT and LHON cybrids
at resting conditions (basal oxygen consumption) and in the presence of 1 µ FCCP (maximal respiratory capacity) after 24-h incubation in glucose medium
supplemented with G+D+Eq (100 n each) or vehicle. Data are mean ± SEM of at least three independent experiments. ####P < 0.0001 for 11778 vehicle versus WT
vehicle (T-student). *P < 0.05, **P < 0.01, ****P < 0.0001 for treated cells versus vehicle (T-student).
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inMnSOD activity and a decrease of O2
− andH2O2, within the first
hour of cell treatment. At later times, but within 24 h, we ob-
served the phytoestrogen-dependent activation ofmitochondrial
biogenesis, which in turn leads to increased cell respiration. Most
importantly, the whole metabolic compensation is specifically
promoted by the ERβ and not by ERα, making possible the avoid-
ance of serious side effects thatwould restrict the use of E2 in vivo.
The proof of principle that we obtained in LHON cybrid cells was
also seen in the patient-derived fibroblasts. Given our previous
demonstration that ERβ is expressed in RGCs (20), there seems
to be great promise in therapy using this approach to mitigate
the neurodegeneration seen in LHON. We propose that this
approach could be of therapeutic value particularly to maintain
the neuroprotection of RGCs in unaffected mutation carriers to
preclude their conversion to vision loss and optic atrophy.
In our study, we looked at the two relevant pathogenic me-
chanisms induced by complex I dysfunction in LHON: impaired
bioenergetics and increased oxidative stress. Both can predispose
to cell death by apoptosis and thus hamper cell viability, as pre-
viously shown in the LHON cybrid cell model (28,31,32,33). Con-
cerning bioenergetics, the phytoestrogen treatment improved
respiration by activating mitochondrial biogenesis and increas-
ing mitochondrial density. This is similar to what we described
for E2 (20) and probably occurs naturally as means for the suc-
cessful compensatory response in adult unaffected individuals
carrying the mutation (21). In our experimental model, the re-
sults also clearly demonstrate the dependence of phytoestrogen
effects on mitochondrial biogenesis from ERβ, and not from ERα.
Furthermore, we also confirm the occurrence of increased oxida-
tive stress in LHON cybrids, and we have been able to rescue cells
Figure 4. Evaluation of oxidative stress in control and LHON cybrids treatedwith phytoestrogens formulation. (A) Mitochondrial superoxide levels (O2−) were evaluated in
treated and untreated cells using the MitoSOX™ Red probe. For immunofluorescence staining, cells were maintained for 1 h in glucose or galactose medium±G+D+Eq
(100 n each), then incubated with MitoSOXTM Red for 15 min, washed and observed under an Olympus IX50 Fluorescence microscope. Representative images of two
experiments on two mutant and two control cybrid clones are shown. O2− levels were quantified by flow cytometry after 1 h of incubation in glucose medium±G+D
+Eq. Data are mean ± SEM of two experiments on two control and two mutant cell lines. ##P < 0.01 for 11778 vehicle versus WT vehicle (T-student). *P < 0.05 for 11778
treated versus 11778 vehicle (T-student). (B) Mitochondrial MnSOD activity was evaluated in treated and untreated cells as described in Materials and Methods and
expressed as units/mg protein. Data are mean ± SEM of eight experiments on two control and two mutant cell lines. *P < 0.05 for treated versus vehicle (T-student).
(C) Cells were maintained 2 h in glucose medium ± G+D+Eq, and then H2O2 levels were evaluated by luminescent assay using the ROS-Glo™ H2O2 assay. Data are
mean ± SEM of two experiments on two control and two mutant cybrid clones. ##P < 0.01 for 11778 vehicle versus WT vehicle (T-student). *P < 0.05 for 11778 treated
versus 11778 vehicle (T-student).
Figure 5. Viability of LHON fibroblasts treated with phytoestrogens. Viability was
evaluated after 72 h of incubation in galactose medium supplemented with G+D
+Eq (100 n each) or vehicle. The number of viable cells in galactose was
normalized to the number of viable cells in glucose at the same time point.
Data are the mean ± SEM of two experiments in duplicate on three affected,
three unaffected carriers and three control cell lines. ##P < 0.01 for 11778 vehicle
versus WT vehicle (T-student), **P < 0.01 for treated cells versus vehicle
(T-student).
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from this pathologic mechanism by phytoestrogen treatment.
However, distinct from the mechanisms on mitochondrial bio-
energetics, the phytoestrogen effect on oxidative stress is acute,
the rescue becoming apparent within the very first hour after
treatment. We interpret this as a direct effect of phytoestrogens
on MnSOD, as shown by our and others previous studies
(20,34,35,36).
The keypoint inusingphytoestrogens as a therapeutic strategy
remains that ERβ largely mediate the compensatory effects on
LHON cells, avoiding the potentially harmful effects on cell prolif-
eration and sexual differentiation. Thus, this approach could be
feasible in patients promoting a rapid translation into clinical
practice. Accordingly, the neuroprotective potential of molecules
targeting the ERβ is currently a hot topic of many pharmacology
research programs (26). An issue for molecules to be used at best
advantage in eye pathology would be the ideal of topical adminis-
tration, as recently investigated with some promising results
in glaucoma (37). Bioavailability to the disease target, the RGCs,
needs to be explored keeping in mind the difficulties with drug
diffusion across the vitreous to the retina.
LHON is characterized by a subacute, rapidly evolving neuro-
degeneration leading to RGC death, probably by apoptosis and
without major inflammatory changes. To date, medical treat-
ments for the acute phase of LOHN have not been truly effective
even in the clinical studies with the quinones, idebenone and
EPI-743 (6,7,8,9). At best these studies showed a better final out-
come of treated patients by increasing the rate of visual recovery,
possibly limiting axonal loss, without stopping the disease
progression in most cases. We envisage phytoestrogens as a pre-
ventive approach specifically for individuals who are non-symp-
tomatic carriers of the LHONmutationwho always remain at risk
of converting. The early and sustained treatment of LHON
patients has better promise to modify the natural history in
preserving RGCs from cell death. Thus, we propose the use of
phytoestrogens primarily for unaffected mutation carriers, in
particular those who present with subclinical changes such as
nerve fiber layer swelling and microangiopathic features (38).
As shown by our studies, the therapeutic strategy based on E2
and phytoestrogens impinges on the same, naturally occurring,
compensatory mechanism we recently reported as central for
LHON penetrance, the activation of mitochondrial biogenesis
(20,21). In fact, on the low pathogenic potential of LHON muta-
tions, ultimately leading to a reduced complex I-driven ATP syn-
thesis rate, an increased mitochondrial density may overcome
the bioenergetic defect inducing an overall increase in the total
ATP levels, aswe previously shown (20), and boosting respiration.
Thus, females may be protected by hormonal modulation (20),
whereas for both genders, there is also an unknown genetically
determined background driving the efficiency in activatingmito-
chondrial biogenesis (21). In addition, our results reveal how phy-
toestrogens rapidly buffer the high levels of oxidative stress in
LHON cells. This antioxidant effect is even more important
than the correction of bioenergetics, as recently corroborated
by the results from the LHON mouse model with ND6 mtDNA
mutation, where the primary pathogenic mechanism was
related to oxidative stress overproduction, and not to ATP
deficiency (39).
In conclusion, the current study provides evidence that phyto-
estrogen can correct in vitro the cellular pathologic phenotype
associated with LHON mutations, in both cybrids and patient-
derived fibroblasts. The natural origin of phytoestrogens makes
these molecules more suited for a rapid translation into clinical
trials, given that synthetic ERβ compounds are not yet validated
for clinical use. The target population for the phytoestrogen
therapy may be the large pool of unaffected mutation carriers
within LHON maternal lineages, who are at high risk of conver-
sion and might benefit from preventive therapy, to avoid vision
loss for the rest of their lives. We would encourage, as a next
step, a trial with these phytoestrogens in the LHON genetic
mouse model.
Materials and Methods
Cell lines and reagents
Fibroblast primary cultures were established from skin biopsies
from three affected and three unaffectedmutation carriers (bear-
ing the homoplasmic m.11778G>A mutation), and from three
normal donors.
Osteosarcoma-derived (143B.TK-) cybrid cell lines were
selected from a previously established collection to match
mtDNA haplogroup between LHON and controls and were as fol-
lows: LHON cybrids bearing the m.11778G>A mutation (HPE9,
haplogroup J1c; HFF3, haplogroup U5a) and controls (HGA, hap-
logroup J1c; HGdA8, haplogroup U1). All the cybrid clones were
previously characterized, and the complete mitochondrial DNA
sequence had been determined (40,41,42).
Fibroblasts and cybrids were grown in high glucose DMEM
(Life Technologies, Warrington, UK) supplemented with dialyzed
fetal bovine serum (15% for fibroblasts and 10% for cybrids) (Life
Technologies), 110 mg/ml sodium pyruvate, 2 m -glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin (Life Technolo-
gies) (referred to as glucosemedium) in a humidified atmosphere
of 95% air and 5% CO2 at 37°C. Experiments were performed both
in glucose medium and in glucose-free DMEM, supplemented
with dialyzed fetal bovine serum, 5 m galactose (Sigma–Aldrich
St Louis, MO, USA) and 110 mg/ml sodium pyruvate (Life Tech-
nologies) (referred to as galactose medium).
17β-estradiol (E2), genistein (G), daidzein (D) and equol (Eq)
were purchased from Sigma–Aldrich; the ERβ antagonist PHTPP
and the ERα antagonist MPP were purchased from Tocris Bio-
science (Bristol, UK). E2 was dissolved in ethanol. The phytoestro-
gens G, D, Eq and the antagonist MPP and PHTPPwere dissolved in
DMSO.
Cell viability
Cell growth was measured by the Trypan blue dye exclusion
assay. Multiple series of 30 mm of diameter (for fibroblasts) and
60 mm of diameter (for cybrids) dishes were seeded with a con-
stant number of cells (either 2 or 3 × 105). Cells were growth either
in glucose or galactose medium (a condition forcing cells to rely
on oxidative metabolism for ATP synthesis) for 24, 48 and 72 h
with the addition of one of the following: E2, G, D and Eq (each
at concentrations of either 100 or 300 n); or a combination of G
plus D plus Eq (each at 100 n). In a subset of experiments,
100 n of either PHTPP or MPP were added 30 min before the in-
cubation of phytoestrogens. Untreated cells were maintained at
the same final ethanol/DMSO concentration. Cells were har-
vested with 0.25% trypsin and 0.2% EDTA, washed, suspended
in PBS in the presence of Trypan blue solution (Sigma–Aldrich)
at 1:1 ratio and counted using a hemocytometer. For each time
point, the number of viable cells in galactose medium was
expressed as a percentage of the number of cells in glucose.
Rate of apoptosis by flow cytometer
To test the rate of apoptosis, treated and untreated cells were
seeded at 0.5–1 × 106 in glucose or galactose medium for 24 h.
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Cells were washed and harvested in Binding Buffer 1× (BD Bios-
ciences, Franklin Lakes, NJ, USA) by scraping to minimize
potentially high annexin V background levels in adherent
cells. Cells were stained with APC-conjugated annexin V (BD
Biosciences) and analyzed on a FACS-Calibur flow cytometer
(BD Biosciences) (43).
Small interfering RNA (siRNA) transfection
A number of 4 × 105 cells were seeded in 60 mm of diameter
dishes and maintained in glucose medium for 24 h. Then, cells
were transfected with 60 pmol of siRNA specific for ERβ or ERα
(ESR2, ESR1; Life Technologies) using Lipofectamine™ RNAiMAX
Transfection Reagent (Life Technologies) according to themanu-
facturer’s protocol. After 24 h, cells were harvested and seeded at
3 × 105 in glucose or galactosemediumplus orminus the combin-
ation of G+D+Eq and to evaluate cell viability. Transfection effi-
ciency was evaluated by western blot analysis.
Oxygen consumption
Oxygen consumption rate (OCR) in adherent cells was measured
with an XFe24 Extracellular Flux Analyzer (Seahorse Bioscience,
Billerica, MA, USA), as previously described (44,45), with minor
variations. Briefly, cells were seeded in XFe24 cell culture micro-
plates at 8 × 103 cells/well in 250 µl of glucose medium and incu-
bated at 37°C in 5% CO2 for 24 h. The day after, the medium was
replacedwith fresh glucosemedium containing vehicle or a com-
bination of G plus D plus Eq (each at 100 n), and cells were incu-
bated for further 24 h. Assays were initiated following the
manufacturer’s instructions by replacing the growth medium in
each well with 525 µl of unbuffered DMEM-high glucose pre-
warmed at 37°C. Cells were incubated at 37°C for 60 min to
allow temperature and pH equilibration. After an OCR baseline
measurement, 75 µl of medium containing oligomycin, FCCP,
rotenone and antimycin A were sequentially added to each well
to reach final concentrations of 1 µ oligomycin, 0.2 µ FCCP,
and 1 µ rotenone and antimycin A. At the end of experiment,
cell content for each well was determined using the colorimetric
sulforhodamine B assay, as previously detailed (46). Data are ex-
pressed as picomoles of O2 per minute per protein content.
As a second approach, we also measured oxygen consump-
tion in treated and untreated intact cells (2-3 × 106) using a
Clark-type oxygen electrode (Hansatech, Norfolk, UK) in 1 ml
DMEM lacking glucose and supplementedwith 10% sodiumpyru-
vate, as described previously (47).
Mitochondrial ATP synthesis
The rate of mitochondrial ATP synthesis wasmeasured in digito-
nin-permeabilized cells by using the luciferin/luciferase assay,
according to the Materials and Methods previously described
(48), with minor modifications (44). Briefly, after trypsinization,
cells (10 × 106/ml) were suspended in a buffer containing
150 m KCl, 25 m Tris–HCl, 2 m EDTA, 0.1% bovine serum al-
bumin, 10 m potassium phosphate, 0.1 mMgCl2, pH 7.4, kept
at room temperature for 15 min, then incubatedwith 50 μg/ml di-
gitonin until 90–100% of cells were positive to Eritrosine B stain-
ing. Aliquots of 3 × 105 permeabilized cells were incubated in the
same buffer in the presence of the adenylate kinase inhibitor P1,
P5-di(adenosine-5′) pentaphosphate (0.1 m), and the CI sub-
strates (1 m malate plus 1 m pyruvate) or the CII substrate
(5 m succinate plus 2 μg/ml rotenone). After addition of
0.1 m ADP, chemiluminescence was determined as a function
of time with a luminometer. The chemiluminescence signal
was calibrated with an internal ATP standard after addition of
10 μ oligomycin. The rates of ATP synthesis were normalized
to protein contents (49) and citrate synthase activity (50). Each
value was the mean based on at least four independent
determinations.
Gene expression by quantitative real-time polymerase
chain reaction
Total RNAwas isolated from treated and untreated cells using SV
Total RNA isolation kit (Promega, Fitchburg, WI, USA) and mea-
sured with a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Total RNA (0.1–1 mg) was
reverse-transcribed to cDNA using random hexamer primers.
The relative expression levels of SIRT1, PPARGC1A (alias PGC1-
α), NRF1, TFAM, POLG, MT-ND6, NDUAF9, MT-COI, COIV, ESR1 and
ESR2 genes were evaluated. We used TaqMan probe chemistry by
means of inventoried FAM-labeled TaqMan® MGB probes (Life
Technologies), according to the manufacturer’s instructions
(Supplementary Material, Table S1). In all samples, the relative
expression of each target gene was evaluated with respect to
one control (reference sample) using the comparative threshold
cycle (ΔCt) method. All values were normalized HPRT1 house-
keeping genes.
Western blot analysis
Treated and untreated cells were rinsed twice with ice-cold PBS,
lysed in ice-cold RIPA buffer (50 m Tris–HCl pH 8, 150 m NaCl,
1%NP-40, 0.5% sodiumdeoxycholate, 1% sodiumdodecyl sulfate,
1 m phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/
ml leupeptin and 10 mg/ml pepstatin) and centrifuged at 10000g
for 10 min at 4°C. For a set of experiments, mitochondria were
isolated from cybrid cells by standard differential centrifugation.
Protein concentration was measured by bicinchoninic acid
(Beyotime Biotechnology, Haimen, China). Equal amount of
protein (40 μg) was separated by precast 4–20% BoltTM Mini Gels
(Life Technologies) and transferred to a polyvinylidene fluoride
membrane. Primary antibodies were visualized using horseradish
peroxidase-conjugated secondary antibodies (Dako, Glostrup,
Denmark). Signals were detected by enhanced chemilumines-
cence (Amersham Biosciences, UK).
The following primary antibodieswere used:mousemonoclo-
nal antibody anti-β-actin (Sigma–Aldrich); rabbit polyclonal
antibody anti-ERα; rabbit polyclonal antibody anti-ERβ; goat poly-
clonal antibody anti-TFAM; rabbit polyclonal antibody anti-NRF1
(Santa Cruz Biotech, Santa Cruz, CA, USA); rabbit polyclonal anti-
body anti-SOD2; rabbit polyclonal antibody anti-ND6; mouse
monoclonal antibody anti-NDUFA9;mousemonoclonal antibody
anti-SDHA; mouse monoclonal antibody anti-COXI; mouse
monoclonal antibody anti-COXIV; mouse monoclonal antibody
anti-CORE2; mouse monoclonal antibody anti-ATPB; mouse
monoclonal antibody anti-VDAC1/Porin (Abcam, Cambridge, UK).
Densitometry was performed using ImageJ64 1.48 v (National
Institute of Health, Bethesda, MD, USA).
Reactive oxygen species evaluation
Mitochondrial superoxide (O2
−) level was evaluated in treated
and untreated cells using a mitochondrial ROS indicator Mito-
SOXTM Red (Invitrogen Molecular Probes, Life Technologies).
Once in the mitochondria, MitoSOXTM reagent is oxidized by
superoxide and exhibits a red fluorescence (with excitation at
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510 nm and emission at 580 nm). For live imaging experiment,
cells were maintained in glucose medium for 1 h, washed with
Hank’s Buffered Salt Solution 1× (HBSS) containing calcium and
magnesium and then incubated with 5 µ MitoSOXTM reagent
for 15 min in the dark at 37°C. After removing MitoSOXTM, cells
werewashedwithHBSS 1× and fluorescent imageswere acquired
with an Olympus IX50 Fluorescence microscope. For flow cyto-
metry, cells were maintained in glucose medium for 1 h, washed
with PBS and treated with 5 µ MitoSOX™ reagent for 30 min in
the dark at 37°C. Then, cells were washed with PBS, collected by
centrifugation, suspended in Binding Buffer 1× (BD Biosciences)
and immediately analyzed with FACS-Calibur flow cytometer
(BD Biosciences).
Levels of hydrogen peroxide (H2O2) were measured by lumi-
nescence assay using a ROS-Glo™ H2O2 Assay (Promega) accord-
ing to themanufacturer’s protocol. A number of 1 × 104 cells were
plated in a 96-well white cell culture plate and incubated over-
night in 100 μl of glucose medium. Then, medium was replaced
by 80 μl of fresh glucose medium plus or minus phytoestrogens,
supplemented with 20 μl of H2O2 Substrate Dilution Buffer con-
taining 125 μ ROS-Glo™ H2O2. After 2-h incubation, 100 μl of
ROS-Glo™ Detection Solution was added and the plate was incu-
bated for 20 min at room temperature. Luminescence was deter-
mined with a GloMax® Multi+ Luminometer. The average RLU of
triplicate samples were calculated.
MnSOD activity was performed as follows. After 1-h incuba-
tion in glucose medium containing a combination of G plus D
plus Eq (each at 100 n), cells were harvested from a 75-cm2
flask, resuspended to 10 × 106/ml in 0.25  Sucrose, 10 m Tris
and 0.2 m EDTA pH 7.6. Then, cells were permeabilized with
100 µg/ml digitonin for 1 min at room temperature and centri-
fuged at 10000g for 5 min at 4°C. The pellet of cells enriched in
mitochondria was resuspended in 0.125 m Tris, 0.1% Triton X-
100 and 2 m KCN pH 7.8. The suspension was immediately
used for MnSOD evaluation, using a Superoxide Dismutase
Assay kit (Sigma–Aldrich) following themanufacturer’s protocol.
The assay kit is designed to measure total SOD activity, but the
presence of KCN in the buffer inhibits both cytosolic Cu/Zn-
SOD and extracellular SOD, resulting largely in the detection of
MnSOD activity alone.
Ultrastructural and histomorphometric analysis
Treated and untreated cells were initially fixed adding in room
temperature 2.5% glutaraldehyde to culture medium in a 1:1
ratio. The culture/fixative mix was transferred into plastic vials
and centrifuged at 10 000g for 10 min at room temperature to gen-
erate a cell pellet. Supernatant was removed, and pellets were
rinsed with PBS buffer, after which final fixation was obtained
storing the pellets with 2.5% glutaraldehyde overnight at 4°C
followed by 1 h of osmium tetroxide fixation.
Tissue dehydration, resin embedding and staining were per-
formed as described (51). Grids were observedwith an FEIMorgag-
ni 268 TEM (FEI Corporate, Hillsboro, OR, USA) and 15 random
fields at 8000× magnification were acquired and stored as TIFF
images (Digital Micrograph 3.4TM, Gatan. GMBH, Munchen, Ger-
many). Image analysis was performed using ImageJ 64 1.48v
(GNU License, National Institute of Health). Mitochondria were
counted, the perimeter of each organelle was manually traced
and the mitochondrial area was automatically measured. Both
the total and the mean cross-sectional mitochondrial area were
then obtained for each acquired field. The cytoplasmic area was
also manually measured for each image, and the ratio between
total mitochondrial area and cytoplasmic area was then derived.
To explore mitochondrial ‘cristae’, high-power magnification
imageswere acquired fromeach group and stored as TIFF images.
Statistical analysis
All data are expressed as mean ± SEM. Data were analyzed by
standardANOVAprocedures followed bymultiple pair-wise com-
parison adjusted with Bonferroni corrections. Chi-square test
was used for frequency data. Significance was considered at
P < 0.05. Numerical estimates were obtained with the GraphPad
InStat 3 version (GraphPad, Inc., San Diego, CA, USA).
Supplementary Material
Supplementary Material is available at HMG online.
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